63659-19-8 Usage
Description
Betaxolol hydrochloride is a cardioselective β1-adrenergic receptor antagonist, a medication that is devoid of intrinsic sympathomimetic and membrane stabilizing properties. It is known for its long duration of action, which allows for once-daily dosing in the treatment of mild to moderate hypertension. Additionally, it is being evaluated for its potential use in glaucoma and has applications in enhancing physical performance in athletes.
Uses
Used in Pharmaceutical Industry:
Betaxolol hydrochloride is used as an antihypertensive agent for the treatment of mild to moderate hypertension. It is effective due to its cardioselective β1-adrenergic blocking properties, which help lower blood pressure with once-daily dosing.
Used in Ophthalmology:
Betaxolol hydrochloride is used as an antiglaucoma agent, being evaluated for its potential in treating glaucoma by reducing intraocular pressure.
Used in Sports Performance Enhancement:
Betaxolol hydrochloride is used as a performance-enhancing substance in sports, where formulations containing β-adrenergic receptor antagonists are utilized to improve physical performance in athletes.
Used in Analytical and Forensic Applications:
Betaxolol hydrochloride is used as an analytical reference standard for forensic applications, serving as a research tool in various analytical processes.
Used in Antifungal Applications:
Betaxolol hydrochloride is also used in antifungal applications, indicating its potential to combat fungal infections.
Originator
Synthelabo (France)
Biological Activity
Selective β 1 -adrenoceptor antagonist.
Check Digit Verification of cas no
The CAS Registry Mumber 63659-19-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,6,5 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 63659-19:
(7*6)+(6*3)+(5*6)+(4*5)+(3*9)+(2*1)+(1*9)=148
148 % 10 = 8
So 63659-19-8 is a valid CAS Registry Number.
InChI:InChI=1/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H
63659-19-8Relevant articles and documents
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE
-
, (2015/02/05)
To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.
Process for the selective alkylation of betaxolol intermediates
-
, (2008/06/13)
The present invention relates to a process for the selective alkylation of intermediates of betaxolol.
